FindTrial
Sign In

Ricolinostat

DRUG5 trials

Sponsors

Dana-Farber Cancer Institute, Mayo Clinic, Regenacy Pharmaceuticals LLC, Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.

Conditions

Fallopian Tube CancerNon-Resectable CholangiocarcinomaOvarian CancerPainful Diabetic Peripheral NeuropathyPeripheral Nervous System DiseasesPrimary Peritoneal CarcinomaRecurrent CholangiocarcinomaStage III Extrahepatic Bile Duct Cancer

Phase 1

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
TerminatedNCT02661815
Dana-Farber Cancer InstituteFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma
Start: 2016-06-15End: 2017-07-28Updated: 2019-11-08
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
WithdrawnNCT02856568
Mayo ClinicNon-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma +10
Start: 2017-05-01End: 2021-10-31Updated: 2017-05-30
Evaluate the Safety and Pharmacokinetics of Ricolinostat
CompletedNCT05193851
Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.Peripheral Nervous System Diseases
Start: 2022-01-12End: 2023-01-06Updated: 2023-04-03
A Study to Investigate the Safety and Efficacy of Ricolinostat
CompletedNCT05229042
Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.Peripheral Nervous System Diseases
Start: 2022-01-01End: 2023-11-10Updated: 2023-12-04

Phase 2

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy
CompletedNCT03176472
Regenacy Pharmaceuticals LLCPainful Diabetic Peripheral Neuropathy
Start: 2020-12-07End: 2023-04-28Updated: 2023-09-21